Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

small-cap

Steer Clear of This NYSE-Listed Biopharmaceutical Play – IBIO

Feb 11, 2022 | Team Kalkine
Steer Clear of This NYSE-Listed Biopharmaceutical Play – IBIO

iBio, Inc. 

Table Description automatically generated

iBio, Inc. (NYSE: IBIO) is a biopharmaceutical developer and the inventor of the sustainable FastPharming Manufacturing System. Using licensed and owned technologies, the company develops novel treatments to prevent fibrotic disorders, malignancies, and infectious diseases. 

Key Highlights: 

  • The company reported a significant decline in revenues to USD 211 thousand in Q1FY22 (ended September 30, 2021) compared to USD 410 thousand in Q1FY21. 
  • IBIO generated 100%of its revenue from three clients in Q1FY22, with two customers accounting for 81%of revenue; losing any customer could negatively influence the company's topline in the future. 
  • IBIO reported an increase in net losses to USD 8.94 million in Q1FY22 from USD 7.53 million in Q1FY21. 
  • In Q1FY22, the company's average receivable days were 2,336 days, compared to the industry median of 60.5 days. 
  • The stock is now trading below its key short-term (50-day) and long-term (200-day) DMA support levels, with the RSI Index at 36.66, indicating a bearish trend. 
  • Stock is leaning towards the lower band of the 52-week range of USD 0.39 to USD 2.83. 
  • IBIO stock price has fallen 66.38and 72.24% inthe past six and nine months, respectively. 

A picture containing chart Description automatically generated 

Three-Year Technical Price Chart (as of February 10, 2022; 12:33 PM ET). Analysis by Kalkine Group 

Conclusion: Considering the bottom-line stress, uncertain outlook, insignificant topline, reliance on specific customers, and other technical indicators, we recommend an "Avoid" rating on the stock at the current price of USD 0.4136, down 1.52% as of February 10, 2022, at 12:33 PM ET. 

*The reference data in this report has been partly sourced from REFINITIV. 

Small-Cap
A Watch on Datadog: Building Competitive Advantage Through Platform Consolidation and AI Adoption
Jun 25, 2026 Team Kalkine
Small-Cap
How SNDG Works: The Mechanics of the Leverage Shares 2X Long SNDK Daily ETF
Jun 25, 2026 Team Kalkine
Blue-Chip
AI-Driven Memory Leadership and Strategic Customer Agreements Strengthen Long-Term Growth Outlook: MU
Jun 25, 2026 Team Kalkine
Small-Cap
Technical Analysis One NASDAQ - Listed IT Services Stock- XNDU
Jun 25, 2026 Team Kalkine
Small-Cap
GCT Semiconductor: Advancing 5G Innovation Through Commercial Expansion and Strategic Partnerships
Jun 25, 2026 Team Kalkine
Disclaimer-

Kalkine Equities LLC provides general information about companies and their securities. The information contained in the reports, including any recommendations regarding the value of or transactions in any securities, does not take into account any of your investment objectives, financial situation or needs. Kalkine Equities LLC is not registered as an investment adviser in the U.S. with either the federal or state government. Before you make a decision about whether to invest in any securities, you should take into account your own objectives, financial situation and needs and seek independent financial advice. All information in our reports represents our views as at the date of publication and may change without notice.

Kalkine Media LLC, an affiliate of Kalkine Equities LLC, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.

Past performance is not a reliable indicator of future performance.